What is claimed is:

~~1. An isolated antibody or antigen-binding fragment thereof that binds human CD3 and induces human T cell proliferation *in vitro* with an EC_{50} of less than about 0.33 pM.~~

~~2. An isolated antibody or antigen-binding fragment thereof that binds human CD3 and induces T cell-mediated killing of tumor cells *in vitro* with an EC_{50} of less than about 2.3 pM.~~

~~3. The isolated antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment thereof induces T cell-mediated killing of tumor cells *in vitro* with an EC_{50} of less than about 1 pM.~~

~~4~~1. An isolated human monospecific antibody ~~or antigen-binding fragment thereof~~ that binds human CD3 with a binding dissociation equilibrium constant (K_D) of less than about 1 nM as measured in a surface plasmon resonance assay at 25ºC, wherein the antibody comprises three complementarity determining regions (CDRs) within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 242, 258, 274, 290, 306, 322, 338, 354, 386, 402, 418, 434, 466, 482, 514, 530, 594, 610, 626, 642, 706, 722, 738, 754, 770, 786, 802, 850, 866, 882, 898, 930, 946, 962, 1026, 1042, 1050, 1058, 1066, 1074, 1082, 1098, 1106, 1114, 1122, 1138, 1146, 1154, 1162, 1170, 1178, and 1186, and three CDRs within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 250, 266, 282, 298, 314, 330, 346, 362, 394, 410, 426, 442, 474, 490, 522, 538, 602, 618, 634, 650, 714, 730, 746, 762, 778, 794, 810, 858, 874, 890, 906, 938, 954, 970, 1034, and 1234.

~~5~~2. The isolated human monospecific antibody ~~or antigen-binding fragment~~ of claim ~~4~~1, wherein the antibody ~~or antigen-binding fragment thereof~~ binds human CD3 with a K_D of less than ~~about~~ 500 pM as measured in a surface plasmon resonance assay at 25ºC.

~~6~~3. The isolated human monospecific antibody ~~or antigen-binding fragment~~ of claim ~~5~~2, wherein the antibody ~~or antigen-binding fragment thereof~~ binds human CD3 with a K_D of less than ~~about~~ 100 pM as measured in a surface plasmon resonance assay at 25ºC.

~~7~~4. ~~An~~ The isolated human monospecific antibody ~~or antigen-binding fragment thereof~~of claim 1 that binds human CD3 with a dissociative half-life (t½) of greater than ~~about~~ 10 minutes as measured in a surface plasmon resonance assay at 25ºC.

~~8~~5. The isolated human monospecific antibody ~~or antigen-binding fragment~~ of claim ~~7~~4, wherein the antibody ~~or antigen-binding fragment thereof~~ binds human CD3 with a t½ of greater than ~~about~~ 100 minutes as measured in a surface plasmon resonance assay at 25ºC.

6. The isolated human monospecific antibody of claim 1, wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 738/746, 754/762, 770/778,

786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, 1026/1034, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

~~9. The antibody or antigen-binding fragment of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof competes for binding to CD3 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.~~

~~10. The antibody or antigen-binding fragment of claim 9, wherein the reference antibody comprises an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; 1050/1234; and 1090/1234.~~

~~11. The antibody or antigen-binding fragment of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on CD3 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.~~

~~12. The antibody or antigen-binding fragment of claim 11, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on CD3 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; 1050/1234; and 1090/1234.~~

~~13. An isolated antibody or antigen-binding fragment thereof that binds human CD3, wherein the antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence as set forth in Table 1; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence as set forth in Table 1.~~

~~14~~7. The isolated human monospecific antibody ~~or antigen-binding fragment~~ of claim ~~13~~6, wherein the antibody ~~or antigen-binding fragment~~ comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; and 1050/1234~~; and 1090/1234~~.

~~15~~8. The isolated human monospecific antibody ~~or antigen-binding fragment~~ of claim ~~14~~7, wherein the antibody ~~or antigen-binding fragment~~ comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16; 116-118-120-124-126-128; 516-518-520-524-526-528; 772-774-776-780-782-784; 1052-1054-1056-1236-1238-1240; and 1092-1094-1096-1236-1238-1240.

9. The isolated human monospecific antibody of claim 1, wherein the antibody comprises: a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 242, 258, 274, 290, 306, 322, 338, 354, 386, 402, 418, 434, 466, 482, 514, 530, 594, 610, 626, 642, 706, 722, 738, 754, 770, 786, 802, 850, 866, 882, 898, 930, 946, 962, 1026, 1042, 1050, 1058, 1066, 1074, 1082, 1098, 1106, 1114, 1122, 1138, 1146, 1154, 1162, 1170, 1178, and 1186; and a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 250, 266, 282, 298, 314, 330, 346, 362, 394, 410, 426, 442, 474, 490, 522, 538, 602, 618, 634, 650, 714, 730, 746, 762, 778, 794, 810, 858, 874, 890, 906, 938, 954, 970, 1034, and 1234.

~~16~~10. ~~An~~ The isolated human monospecific antibody ~~or antigen-binding fragment thereof~~ of claim 9 that binds human CD3, wherein the antibody ~~or antigen-binding fragment~~ comprises: (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2; 114; 514; 770; and 1050; ~~and 1090;~~ and (b) a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10; 122; 522; 778; 1234; and 1234.

11. The isolated human monospecific antibody of claim 9, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 738/746, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, 1026/1034, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

~~17~~12. The isolated human monospecific antibody ~~or antigen-binding fragment~~ of claim ~~16~~10, wherein the antibody ~~or antigen-binding fragment~~ comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; and 1050/1234~~; and 1090/1234~~.

13. The isolated human monospecific antibody of claim 9, wherein the antibody induces human T-cell proliferation and monkey T-cell proliferation in vitro, and wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 738/746, 770/778, 786/794, 802/810, 866/874, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

14. The isolated human monospecific antibody of claim 13, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 738/746, 770/778, 786/794, 802/810, 866/874, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

~~18. A bispecific antibody comprising a first antigen-binding domain that binds human CD3 and a second antigen-binding domain that binds a target antigen, wherein the first antigen-binding domain is derived from the antibody or antigen-binding fragment of any one of claims 1 to 17.~~

~~19~~15. A pharmaceutical composition comprising the antibody ~~or antigen-binding fragment~~ of any one of claims 1 to ~~17~~14~~, or the bispecific antibody of claim 18~~, and a pharmaceutically acceptable carrier or diluent.

~~20. Use of a pharmaceutical composition of claim 19 for the manufacture of a medicament for upmodulating an immune response in a subject.~~

~~21~~16. Use of a pharmaceutical composition of claim ~~19~~15 ~~for~~ in the manufacture of a medicament for treating a tumor in a subject in need thereof.

~~22. A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20.~~

~~23. The bispecific antigen-binding molecule of claim 22, wherein the antigen-binding molecule binds to CD3-expressing human T-cells with an EC_{50} value of between $1x10^{-12}$ M and $1x10^{-6}$ M.~~

~~24. The bispecific antigen-binding molecule of claim 22, wherein the antigen-binding molecule binds to CD3-expressing human T-cells with an EC_{50} value of between $1x10^{-9}$ M and $1x10^{-8}$ M.~~

~~25. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule binds human cells expressing human CD3 and cynomolgus monkey cells expressing cynomolgus CD3.~~

~~26. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule induces proliferation of human and cynomolgus peripheral blood mononuclear cells (PBMCs) *in vitro*.~~

~~27. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule induces IFN-gamma release and CD25 up-regulation in human whole blood.~~

~~28. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule induces T-cell mediated cytotoxicity of human B-cells.~~

~~29. The bispecific antigen-binding molecule of claim 28, wherein the antigen-binding molecule induces T-cell mediated cytotoxicity of human B-cells that are resistant to or refractory to anti-CD20-mediated cytotoxicity.~~

~~30. The bispecific antigen-binding molecule of any one of claims 22 to 29, wherein a single administration of the bispecific antigen-binding molecule to a subject at a dose of about 0.01 mg/kg causes a reduction in the number of B cells in the subject below detectable levels by about day 1 after administration of the bispecific antigen-binding molecule to the subject.~~

~~31. The bispecific antigen-binding molecule of claim 30, wherein the number of B-cells remains below detectable levels until at least about 14 days after administration of a single dose of about 0.01 mg/kg of the bispecific antigen-binding molecule to the subject.~~

~~32. The bispecific antigen-binding molecule of claim 30 or 31, wherein the number of B-cells per microliter of blood drawn from the subject at about day 1 through about day 28 after administration of a single dose of about 0.01 mg/kg of the antigen-binding molecule to the subject is less than 25% the number of B-cells per microliter of blood drawn from the subject prior to administration of the bispecific antigen-binding molecule.~~

~~33. The bispecific antigen-binding molecule of claim 30 or 31, wherein the number of B-cells per microliter of blood drawn from the subject at about day 1 through about day 56 after administration of a single dose of about 0.01 mg/kg of the antigen-binding molecule to the subject is less than 50%~~

~~the number of B cells per microliter of blood drawn from the subject prior to administration of the bispecific antigen-binding molecule.~~

~~34. The bispecific antigen-binding molecule of any one of claims 30 to 33, wherein the number of T cells per microliter of blood drawn from the subject at about day 14 through about day 56 after administration of the antigen-binding molecule to the subject is equal to or greater than the number of T cells per microliter of blood drawn from the subject prior to administration of the bispecific antigen-binding molecule.~~

~~35. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain that specifically binds human CD3 comprises the heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) from a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1250, 1266, 1282, 1298, 1314 and 1329, and the light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1258, 1274, 1290, 1306, 1322 and 1333.~~

~~36. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain that specifically binds human CD20 comprises the heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) comprising SEQ ID NO:1242, and the light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1258, 1274, 1290, 1306, 1322 and 1333.~~

~~37. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316 and 1330; wherein A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1254, 1270, 1286, 1302, 1318 and 1331; wherein A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320 and 1332, wherein A1-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A1-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A1-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.~~

~~38. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:1244, wherein A2-HCDR2 comprises the amino acid sequence of SEQ ID NO:1246, wherein A2-HCDR3 comprises SEQ ID NO:1248, wherein A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1260, 1276, 1292, 1308, 1324 and 1334, wherein A2-LCDR2 comprises an amino acid sequence selected from the~~

group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

39. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), and wherein the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3);

wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316 and 1330; wherein A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1254, 1270, 1286, 1302, 1318 and 1331; wherein A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320 and 1332, wherein A1-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A1-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A1-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336; and

wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:1244, wherein A2-HCDR2 comprises the amino acid sequence of SEQ ID NO:1246, wherein A2-HCDR3 comprises SEQ ID NO:1248, wherein A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A2-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

40. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316 and 1330; wherein A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1254, 1270, 1286, 1302, 1318 and 1331; wherein A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320 and 1332, wherein A1-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A1-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A1-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

41. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding

protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1250, 1266, 1282, 1298, 1314 and 1329, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333.

42. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain competes for binding to human CD20 with a reference antigen-binding protein comprising three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:1244, wherein A2-HCDR2 comprises the amino acid sequence of SEQ ID NO:1246, wherein A2-HCDR3 comprises SEQ ID NO:1248, wherein A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A2-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

43. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain competes for binding to human CD20 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1242, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333.

44. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1250, 1266, 1282, 1298, 1314 and 1329, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333; and wherein the second antigen-binding domain competes for binding to human CD20 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1242, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333.

45. A pharmaceutical composition comprising a bispecific antigen-binding molecule of any one of claims 22 to 44 and a pharmaceutically acceptable carrier or diluent.

46. Use of a pharmaceutical composition of claim 45 for the manufacture of a medicament for treating a B-cell cancer in a subject.

47. The use of claim 46, wherein the B-cell cancer is selected from the group consisting of: follicular lymphoma, B-cell chronic lymphocytic leukemia, B-cell lymphoblastic lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, Mantle cell lymphoma, hairy cell leukemia and Burkitt lymphoma.

48. The use of claim 46 or 47, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone.

~~49. The use of claim 48, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to rituximab monotherapy.~~

~~50. The use of any one of claims 46 through 49, wherein the subject has received an anti-CD20 monospecific antibody therapy at least 1 day to 1 year prior to the administration of the pharmaceutical composition.~~

~~51. The use of claim 50, wherein the anti-CD20 monospecific therapy comprises or consists of an anti-CD20 mono-specific antibody.~~

~~52. The use of claim 51, wherein the anti-CD20 mono-specific antibody is rituximab.~~

~~53. Use of a pharmaceutical composition of claim 45 for the manufacture of a medicament for treating a B-cell cancer in a subject wherein the subject is selected on the basis of who is afflicted with a tumor that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone.~~

~~54. The use of claim 53, wherein the subject is selected on the basis of having a tumor that is resistant to, refractory to, or incompletely responsive to rituximab monotherapy.~~

What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof that binds human CD3 and induces human T cell proliferation *in vitro* with an EC_{50} of less than about 0.33 pM.

2. An isolated antibody or antigen-binding fragment thereof that binds human CD3 and induces T cell-mediated killing of tumor cells *in vitro* with an EC_{50} of less than about 2.3 pM.

3. The isolated antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment thereof induces T cell-mediated killing of tumor cells *in vitro* with an EC_{50} of less than about 1 pM.

4. An isolated antibody or antigen-binding fragment thereof that binds human CD3 with a binding dissociation equilibrium constant (K_D) of less than about 1 nM as measured in a surface plasmon resonance assay at 25ºC.

5. The isolated antibody or antigen-binding fragment of claim 4, wherein the antibody or antigen-binding fragment thereof binds human CD3 with a K_D of less than about 500 pM as measured in a surface plasmon resonance assay at 25ºC.

6. The isolated antibody or antigen-binding fragment of claim 5, wherein the antibody or antigen-binding fragment thereof binds human CD3 with a K_D of less than about 100 pM as measured in a surface plasmon resonance assay at 25ºC.

7. An isolated antibody or antigen-binding fragment thereof that binds human CD3 with a dissociative half-life (t½) of greater than about 10 minutes as measured in a surface plasmon resonance assay at 25ºC.

8. The isolated antibody or antigen-binding fragment of claim 7, wherein the antibody or antigen-binding fragment thereof binds human CD3 with a t½ of greater than about 100 minutes as measured in a surface plasmon resonance assay at 25ºC.

9. The antibody or antigen-binding fragment of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof competes for binding to CD3 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.

10. The antibody or antigen-binding fragment of claim 9, wherein the reference antibody comprises an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; 1050/1234; and 1090/1234.

11. The antibody or antigen-binding fragment of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on CD3 as a reference

antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.

12. The antibody or antigen-binding fragment of claim 11, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on CD3 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; 1050/1234; and 1090/1234.

13. An isolated antibody or antigen-binding fragment thereof that binds human CD3, wherein the antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence as set forth in Table 1; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence as set forth in Table 1.

14. The isolated antibody or antigen-binding fragment of claim 13, wherein the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; 1050/1234; and 1090/1234.

15. The isolated antibody or antigen-binding fragment of claim 14, wherein the antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16; 116-118-120-124-126-128; 516-518-520-524-526-528; 772-774-776-780-782-784; 1052-1054-1056-1236-1238-1240; and 1092-1094-1096-1236-1238-1240.

16. An isolated antibody or antigen-binding fragment thereof that binds human CD3, wherein the antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2; 114; 514; 770; 1050; and 1090; and (b) a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10; 122; 522; 778; 1234; and 1234.

17. The isolated antibody or antigen-binding fragment of claim 16, wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; 1050/1234; and 1090/1234.

18. A bispecific antibody comprising a first antigen-binding domain that binds human CD3 and a second antigen-binding domain that binds a target antigen, wherein the first antigen-binding domain is derived from the antibody or antigen-binding fragment of any one of claims 1 to 17.

19. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 17, or the bispecific antibody of claim 18, and a pharmaceutically acceptable carrier or diluent.

20. Use of a pharmaceutical composition of claim 19 for the manufacture of a medicament for upmodulating an immune response in a subject.

21. Use of a pharmaceutical composition of claim 19 for the manufacture of a medicament for treating a tumor in a subject in need thereof.

22. A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding domain that specifically binds human CD20.

23. The bispecific antigen-binding molecule of claim 22, wherein the antigen-binding molecule binds to CD3-expressing human T-cells with an EC_{50} value of between $1x10^{-12}$ M and $1x10^{-6}$ M.

24. The bispecific antigen-binding molecule of claim 22, wherein the antigen-binding molecule binds to CD3-expressing human T-cells with an EC_{50} value of between $1x10^{-9}$ M and $1x10^{-8}$ M.

25. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule binds human cells expressing human CD3 and cynomolgus monkey cells expressing cynomolgus CD3.

26. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule induces proliferation of human and cynomolgus peripheral blood mononuclear cells (PBMCs) *in vitro*.

27. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule induces IFN-gamma release and CD25 up-regulation in human whole blood.

28. The bispecific antigen-binding molecule of any one of claims 22 to 24, wherein the antigen-binding molecule induces T-cell mediated cytotoxicity of human B-cells.

29. The bispecific antigen-binding molecule of claim 28, wherein the antigen-binding molecule induces T-cell mediated cytotoxicity of human B-cells that are resistant to or refractory to anti-CD20-mediated cytotoxicity.

30. The bispecific antigen-binding molecule of any one of claims 22 to 29, wherein a

single administration of the bispecific antigen-binding molecule to a subject at a dose of about 0.01 mg/kg causes a reduction in the number of B cells in the subject below detectable levels by about day 1 after administration of the bispecific antigen-binding molecule to the subject.

31. The bispecific antigen-binding molecule of claim 30, wherein the number of B-cells remains below detectable levels until at least about 14 days after administration of a single dose of about 0.01 mg/kg of the bispecific antigen-binding molecule to the subject.

32. The bispecific antigen-binding molecule of claim 30 or 31, wherein the number of B-cells per microliter of blood drawn from the subject at about day 1 through about day 28 after administration of a single dose of about 0.01 mg/kg of the antigen-binding molecule to the subject is less than 25% the number of B-cells per microliter of blood drawn from the subject prior to administration of the bispecific antigen-binding molecule.

33. The bispecific antigen-binding molecule of claim 30 or 31, wherein the number of B-cells per microliter of blood drawn from the subject at about day 1 through about day 56 after administration of a single dose of about 0.01 mg/kg of the antigen-binding molecule to the subject is less than 50% the number of B-cells per microliter of blood drawn from the subject prior to administration of the bispecific antigen-binding molecule.

34. The bispecific antigen-binding molecule of any one of claims 30 to 33, wherein the number of T cells per microliter of blood drawn from the subject at about day 14 through about day 56 after administration of the antigen-binding molecule to the subject is equal to or greater than the number of T cells per microliter of blood drawn from the subject prior to administration of the bispecific antigen-binding molecule.

35. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain that specifically binds human CD3 comprises the heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) from a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1250, 1266, 1282, 1298, 1314 and 1329, and the light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1258, 1274, 1290, 1306, 1322 and 1333.

36. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain that specifically binds human CD20 comprises the heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) comprising SEQ ID NO:1242, and the light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR)

comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1258, 1274, 1290, 1306, 1322 and 1333.

37. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316 and 1330; wherein A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1254, 1270, 1286, 1302, 1318 and 1331; wherein A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320 and 1332, wherein A1-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A1-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A1-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

38. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:1244, wherein A2-HCDR2 comprises the amino acid sequence of SEQ ID NO:1246, wherein A2-HCDR3 comprises SEQ ID NO:1248, wherein A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1260, 1276, 1292, 1308, 1324 and 1334, wherein A2-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

39. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), and wherein the second antigen-binding domain that specifically binds human CD20 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3);

wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316 and 1330; wherein A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1254, 1270, 1286, 1302, 1318 and 1331; wherein A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320 and 1332, wherein A1-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A1-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A1-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336; and

wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:1244, wherein A2-HCDR2 comprises the amino acid sequence of SEQ ID NO:1246, wherein A2-HCDR3 comprises SEQ ID NO:1248, wherein A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A2-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

40. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316 and 1330; wherein A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1254, 1270, 1286, 1302, 1318 and 1331; wherein A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320 and 1332, wherein A1-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A1-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A1-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

41. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1250, 1266, 1282, 1298, 1314 and 1329, and a light chain variable region (LCVR) comprising an amino acid sequence

selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333.

42. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain competes for binding to human CD20 with a reference antigen-binding protein comprising three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises the amino acid sequence of SEQ ID NO:1244, wherein A2-HCDR2 comprises the amino acid sequence of SEQ ID NO:1246, wherein A2-HCDR3 comprises SEQ ID NO:1248, wherein A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324 and 1334, wherein A2-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326 and 1335, and wherein A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328 and 1336.

43. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the second antigen-binding domain competes for binding to human CD20 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1242, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333.

44. The bispecific antigen-binding molecule of any one of claims 22 to 34, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1250, 1266, 1282, 1298, 1314 and 1329, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333; and wherein the second antigen-binding domain competes for binding to human CD20 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1242, and a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333.

45. A pharmaceutical composition comprising a bispecific antigen-binding molecule of any one of claims 22 to 44 and a pharmaceutically acceptable carrier or diluent.

46. Use of a pharmaceutical composition of claim 45 for the manufacture of a medicament for treating a B-cell cancer in a subject.

47. The use of claim 46, wherein the B-cell cancer is selected from the group consisting of: follicular lymphoma, B cell chronic lymphocytic leukemia, B cell lymphoblastic lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma, diffuse large B cell lymphoma, marginal zone lymphoma, Mantle cell lymphoma, hairy cell leukemia and Burkitt lymphoma.

48. The use of claim 46 or 47, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone.

49. The use of claim 48, wherein the subject is afflicted with a tumor that is resistant to, or incompletely responsive to rituximab monotherapy.

50. The use of any one of claims 46 through 49, wherein the subject has received an anti-CD20 monospecific antibody therapy at least 1 day to 1 year prior to the administration of the pharmaceutical composition.

51. The use of claim 50, wherein the anti-CD20 monospecific therapy comprises or consists of an anti-CD20 mono-specific antibody.

52. The use of claim 51, wherein the anti-CD20 mono-specific antibody is rituximab.

53. Use of a pharmaceutical composition of claim 45 for the manufacture of a medicament for treating a B-cell cancer in a subject wherein the subject is selected on the basis of who is afflicted with a tumor that is resistant to, or incompletely responsive to anti-CD20 monospecific therapy alone.

54. The use of claim 53, wherein the subject is selected on the basis of having a tumor that is resistant to, refractory to, or incompletely responsive to rituximab monotherapy.

What is claimed is:

1. An isolated human monospecific antibody that binds human CD3 with a binding dissociation equilibrium constant (K_D) of less than about 1 nM as measured in a surface plasmon resonance assay at 25ºC, wherein the antibody comprises three complementarity determining regions (CDRs) within a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 242, 258, 274, 290, 306, 322, 338, 354, 386, 402, 418, 434, 466, 482, 514, 530, 594, 610, 626, 642, 706, 722, 738, 754, 770, 786, 802, 850, 866, 882, 898, 930, 946, 962, 1026, 1042, 1050, 1058, 1066, 1074, 1082, 1098, 1106, 1114, 1122, 1138, 1146, 1154, 1162, 1170, 1178, and 1186, and three CDRs within a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 250, 266, 282, 298, 314, 330, 346, 362, 394, 410, 426, 442, 474, 490, 522, 538, 602, 618, 634, 650, 714, 730, 746, 762, 778, 794, 810, 858, 874, 890, 906, 938, 954, 970, 1034, and 1234.

2. The isolated human monospecific antibody of claim 1, wherein the antibody binds human CD3 with a K_D of less than 500 pM as measured in a surface plasmon resonance assay at 25ºC.

3. The isolated human monospecific antibody of claim 2, wherein the antibody binds human CD3 with a K_D of less than 100 pM as measured in a surface plasmon resonance assay at 25ºC.

4. The isolated human monospecific antibody of claim 1 that binds human CD3 with a dissociative half-life (t½) of greater than 10 minutes as measured in a surface plasmon resonance assay at 25ºC.

5. The isolated human monospecific antibody of claim 4, wherein the antibody binds human CD3 with a t½ of greater than 100 minutes as measured in a surface plasmon resonance assay at 25ºC.

6. The isolated human monospecific antibody of claim 1, wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 738/746, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, 1026/1034, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

7. The isolated human monospecific antibody of claim 6, wherein the comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; and 1050/1234.

8. The isolated antibody of claim 7, wherein the antibody comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs: 4-6-8-12-14-16; 116-118-120-124-126-128; 516-518-520-524-526-528; 772-774-776-780-782-784; 1052-1054-1056-1236-1238-1240; and 1092-1094-1096-1236-1238-1240.

9. The isolated human monospecific antibody of claim 1, wherein the antibody comprises: a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 242, 258, 274, 290, 306, 322, 338, 354, 386, 402, 418, 434, 466, 482, 514, 530, 594, 610, 626, 642, 706, 722, 738, 754, 770, 786, 802, 850, 866, 882, 898, 930, 946, 962, 1026, 1042, 1050, 1058, 1066, 1074, 1082, 1098, 1106, 1114, 1122, 1138, 1146, 1154, 1162, 1170, 1178, and 1186; and a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 250, 266, 282, 298, 314, 330, 346, 362, 394, 410, 426, 442, 474, 490, 522, 538, 602, 618, 634, 650, 714, 730, 746, 762, 778, 794, 810, 858, 874, 890, 906, 938, 954, 970, 1034, and 1234.

10. The isolated human monospecific antibody of claim 9 that binds human CD3, wherein the antibody comprises: (a) a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2; 114; 514; 770; and 1050; and (b) a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10; 122; 522; 778; 1234; and 1234.

11. The isolated human monospecific antibody of claim 9, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 386/394, 402/410, 418/426, 434/442, 466/474, 482/490, 514/522, 530/538, 594/602, 610/618, 626/634, 642/650, 706/714, 722/730, 738/746, 754/762, 770/778, 786/794, 802/810, 850/858, 866/874, 882/890, 898/906, 930/938, 946/954, 962/970, 1026/1034, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

12. The isolated human monospecific antibody of claim 10, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 114/122; 514/522; 770/778; and 1050/1234.

13. The isolated human monospecific antibody of claim 9, wherein the antibody induces human T-cell proliferation and monkey T-cell proliferation in vitro, and wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 738/746, 770/778, 786/794, 802/810, 866/874, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

14. The isolated human monospecific antibody of claim 13, wherein the antibody comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 114/122, 706/714, 722/730, 738/746, 770/778, 786/794, 802/810, 866/874, 1042/1234, 1050/1234, 1058/1234, 1066/1234, 1074/1234, 1082/1234, 1098/1234, 1106/1234, 1114/1234, 1122/1234, 1138/1234, 1146/1234, 1154/1234, 1162/1234, 1170/1234, 1178/1234, and 1186/1234.

15. A pharmaceutical composition comprising the antibody of any one of claims 1 to 14, and a pharmaceutically acceptable carrier or diluent.

16. Use of a pharmaceutical composition of claim 15 in the manufacture of a medicament for treating a tumor in a subject in need thereof.